Neurology Text Module

CE / CME

Integrating Brain Health Discussions Into Clinical Practice: Neurology

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Released: March 27, 2025

Expiration: March 26, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. World Health Organization (WHO). Optimizing brain health across the life course: WHO position paper. 2022. iris.who.int/handle/10665/361251. Accessed March 24, 2025.
  2. Rost NS, Salinas J, Jordan JT, et al. The brain health imperative in the 21st century-A call to action: The AAN brain health platform and position statement. Neurology. 2023;101:570-579.
  3. 2024 Alzheimer's disease facts and figures. Alzheimers Dement. 2024;20:3708-3821.
  4. Jia J, Ning Y, Chen M, et al. Biomarker changes during 20 years preceding Alzheimer's disease. N Engl J Med. 2024;390:712-722.
  5. Hajjo R, Sabbah DA, Abusara OH, et al. A review of the recent advances in Alzheimer's disease research and the utilization of network biology approaches for prioritizing diagnostics and therapeutics. Diagnostics (Basel). 2022;12.
  6. Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3-45 study: Design of a prevention trial for Alzheimer's disease. Alzheimers Dement. 2023;19:1227-1233.
  7. Alzheimer’s Prevention Initiative. Alzheimer’s prevention initiative studies. alzheimerspreventioninitiative.com/api-studies/. Accessed March 24, 2025.
  8. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512-527.
  9. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388:9-21.
  10. Van Dyck C. Does the current evidence base support lecanemab continued dosing for early Alzheimer's disease? Presented at: Clinical Trials for Alzheimer's Disease Annual Meeting; October 29-November 1, 2024.
  11. Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784.
  12. Khan AD, Elnagar S, Eltayeb M, et al. The impact of hypertension on cognitive decline and Alzheimer's disease and its management: A systematic review. Cureus. 2024;16:e65194.
  13. Pillai JA, Bena J, Bekris L, et al. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease. Alzheimers Res Ther. 2023;15:54.
  14. Nguyen Ho PT, Hoepel SJW, Rodriguez-Ayllon M, et al. Sleep, 24-hour activity rhythms, and subsequent amyloid-beta pathology. JAMA Neurol. 2024;81:824-834.
  15. Ramos-Cejudo J, Wisniewski T, Marmar C, et al. Traumatic brain injury and Alzheimer's disease: The cerebrovascular link. EBioMedicine. 2018;28:21-30.
  16. Toda T, Parylak SL, Linker SB, et al. The role of adult hippocampal neurogenesis in brain health and disease. Mol Psychiatry. 2019;24:67-87.
  17. Lee WC, Bonin V, Reed M, et al. Anatomy and function of an excitatory network in the visual cortex. Nature. 2016;532:370-374.
  18. Dubois B, Villain N, Schneider L, et al. Alzheimer disease as a clinical-biological construct-An International Working Group recommendation. JAMA Neurol. 2024;81:1304-1311.
  19. Jack CR, Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20:5143-5169.
  20. Mormino EC, Papp KV. Amyloid accumulation and cognitive decline in clinically normal older individuals: Implications for aging and early Alzheimer's disease. J Alzheimers Dis. 2018;64:S633-S646.
  21. Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381-2387.
  22. Atri A, Dickerson BC, Clevenger C, et al. Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. Alzheimers Dement. 2024.